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Abstract
The report concerns the molecular epidemiology, cyclohexane tolerance and Phe-Arg-b-naphtylamide (PAbN) susceptibility of multi-
drug-resistant Enterobacter cloacae isolates, with high-level ﬂuoroquinolone resistance collected from healthcare facilities in a nationwide
survey. A total of 113 multidrug-resistant E. cloacae isolates (recovered in 1997–2005) were subjected to disc diffusion tests, ERIC-PCR
and XbaI PFGE. Representatives of the ERIC-types (n = 67) were tested further with cyclohexane and PAbN, using ciproﬂoxacin as the
substrate. Forty-four per cent of the isolates were derived from the urinary tract, 19% from the bloodstream, 17% from the respiratory
tract, and 15% from wound infections. Four ERIC-types (A, B, C and D) were distinguished, but 109 isolates were found to belong to a
single, epidemic ERIC type: A. PFGE results suggested that the epidemic-type isolates were of monoclonal origin. Forty-two patients
were involved in four outbreaks caused by the epidemic-type strains. Eighty-one cases were found to be nosocomial. At least fourfold
reduction in ciproﬂoxacin MICs was found in the presence of PAbN in 79% of representative isolates (representing types A, C and D);
an eightfold or greater reduction in ciproﬂoxacin MICs in the presence of PAbN (PAbN+) was found in 37% of representative isolates,
representing types A and C. Eighty-ﬁve per cent of the representative isolates were found to be cyclohexane-tolerant, representing
types A, C and D. This is the ﬁrst report of a wide distribution of cyclohexane-tolerant or PAbN+ strains of E. cloacae. These feature-
indicators of adaptive mechanisms that help bacteria to survive in hospital wards may have contributed to the nationwide spread of type
A strains.
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Introduction
Enterobacter cloacae is a prevalent opportunistic pathogen
repeatedly associated with sporadic or clustered cases of
infection acquired in hospital. Multidrug resistance (MDR)
is a property that may account for the maintenance of
bacterial clones in hospital environments under high antibi-
otic pressure. A nationwide survey was initiated after high
incidence of MDR and coincidence of MDR with high-level
ciproﬂoxacin resistance was recognized in 2001 among
third-generation cephalosporin-resistant E. cloacae isolates
at the Hungarian National Center for Epidemiology
(HNCE).
Cyclohexane tolerance of gram-negative bacteria is a
well-known indicator of the presence of cell membrane-asso-
ciated resistance mechanisms [1], but only one cyclohexane-
tolerant E. cloacae isolate has been reported so far [2].
Reported here is a wide distribution of cyclohexane toler-
ance among the multidrug-resistant isolates collected.
Materials and Methods
Clinical settings
Hungarian microbiological laboratories were asked (in
November 2001) to submit multidrug-resistant E. cloacae iso-
lates, with their personal and institutional data. MDR was
deﬁned as resistance to third-generation cephalosporin,
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ciproﬂoxacin and a third, non-b-lactam, non-ﬂuoroquinolone
agent.
Bacterial strains
Eighty-six isolates were submitted from 11 Hungarian coun-
ties. A further 27 isolates collected by the HNCE in previous
years were also drawn into the study.
The laboratory control strains were E. coli ATCC 25922
(biochemical identiﬁcation and antimicrobial susceptibility
testing), K. pneumoniae ATCC 700603 (ESBL screening),
E. cloacae ATCC 13047 (biochemical identiﬁcation, antimi-
crobial susceptibility testing, ERIC-PCR, PFGE, cyclohexane
and PAbN tests).
Biochemical identiﬁcation
Biochemical identiﬁcation of all isolates was performed
using the API 20E identiﬁcation system (bioMerieux, Marcy
L’Etoile, France) according to the manufacturer’s instruc-
tions.
Antimicrobial susceptibility testing
ESBL screening [3] and further disc diffusion tests [4] for im-
ipenem, ciproﬂoxacin (Cip), gentamicin (Gn), tobramycin
(Tob), netilmicin (Net), amikacin (Ak), streptomycin (S), chl-
oramphenicol (C), tetracycline (Te), nitrofurantoin (Ni) and
trimethoprim-sulfamethoxazole (Sxt) were carried out using
Oxoid discs (Oxoid, Basingstoke, UK). The MICs for cipro-
ﬂoxacin, chloramphenicol and tetracycline (Sigma-Aldrich
Chemie, Steinheim, Germany) were determined as recom-
mended by the CLSI [4].
DNA tests
PCR reactions for (i) ERIC sequences [5,6], (ii) quinolone
resistance-determining regions (QRDRs) of gyrA and parC
genes [2] and (iii) blaSHV and blaCTX-M genes [7,8] were per-
formed by standard techniques. The sequencing of PCR
products was performed as described previously [9]. DNA
sequences were analysed by using BLASTN (http://
www.ncbi.nlm.nih.gov/BLAST/).
DNA blocks for PFGE [10] were digested according to
the manufacturer’s instructions with XbaI (New England
BioLabs, Hitchin, UK), NotI (New England BioLabs) [11] and
SpeI (New England BioLabs) [12]. PFGE was performed as
described previously [9]. DNA gels were subjected to visual
examination; computer-assisted analysis was performed with
Quantity-one or Fingerprinting II softwares (Bio-Rad Labora-
tories California, CA, USA). Results of the ERIC-PCR and
the PFGE examinations were evaluated in accordance with
recent publications [13,14].
Organic solvent tolerance test
Organic solvent tolerance was examined with cyclohexane
(Sigma-Aldrich) by repeated testing as described by White
et al. [15]. Brieﬂy: (i) strains were allowed to grow to the late
logarithmic phase, (ii) cultures were diluted to a concentra-
tion of approximately 105 CFU/mL, (iii) a 500-lL aliquot of
each bacterial suspension was plated on LB agar (Difco,
Detroit, MI, USA) and allowed to dry, (iv) cyclohexane was
overlaid to a depth of 2–3 mm, and (v) the plates were sealed
and incubated overnight at 30C. Efﬁciency of plating was
checked with a parallel series of inoculated plates incubated
without cyclohexane under the same conditions. Reproduc-
ibility was determined by repeated testing: two independent
suspensions of each strain were obtained from single-colony
cultures prepared from the stock cultures at different times.
Growth was recorded as conﬂuent growth (+), visible growth
(£100 colonies; +/)) or no growth ()) [15].
Efﬂux pump inhibitor test with Phe-Arg-b-naphtylamide
(PAbN)
The efﬂux-pump inhibitor test was performed with Phe-Arg-
b-naphtylamide (Sigma-Aldrich) as described by Lomovskaya
et al. [16].
Results
Analysis of data sheets
The total collection of isolates were derived from 25 Hun-
garian healthcare facilities (Table 1). The reported diagnoses
were urinary-tract infection (46 patients, 38 of them with
positive anamnesis for urinary-tract catheter), sepsis (19
patients, four of them with urosepsis), wound infection (19
patients) and respiratory tract infection (nine patients, seven
of them with well-documented VAP, all with positive anam-
nesis for mechanical ventilation). Four outbreaks (involving
altogether 42 patients) were reported by the senders.
Eighty-one cases were considered nosocomial according to
the deﬁnition of CDC; some required clinical data were
missing in a further 10 cases.
Disc diffusion tests, ERIC-PCR and PFGE
The results of tests performed on all the isolates (antimicro-
bial susceptibility testing, ERIC-PCR and XbaI PFGE) and the
results of ESBL-PCR sequencing are summarized in Table 1.
The ESBL-negative isolates (n = 110) showed the typical
resistance pattern of de-repressed AmpC mutants [3]. No
carbapenem resistance was detected. Resistance rates to Ni,
Ak, Gn, C, Net, Tob, Te, S and Sxt were 30%, 32%, 63%,
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TABLE 1. Clinical data and results of laboratory tests performed on all the isolates
Isolationa HF ID/depb Sample Antibiogramc
ERIC-type/XbaI
cluster/strain
1997 1/og Woundd GnNetSxtS A/c1/P1
1998 2/gm Urined GnTobTeSxtS A/c1/P2
1998 2/gm Urined NetTeSxtS A/c1/P3
1998 3/orth Woundd GnTobCTeSxtS A/c1/P1-v1
1998 2/gm Punctured GnTobNet(Ak)CTeSxtS A/c2/P4
1998 4/pulm Sputumd GnTobNet(Ak)CTeSxtS A/c2/P5
2000-05 5/urol Urined TobNetAkCTeNiSxtS (n = 4) A/c1/P6-v1
2000-05 5/urol Urined GnTobNet(Ak)CTeSxtS (n = 4) A/c1/P6
2000-05 5/urol Urined AkCTeNiSxtS A/c1/P6-v4
2000-05 5/urol Urined NetCTeSxtS A/c2/P4-v1
2000-05 5/urol Bloodd TobNet(Ak)CTeSxtS A/c2/P4-v2
2000-05 5/urol IV cannula GnTobNet(Ak)CTeSxtS A/c2/P4-v2
2000-05 5/urol Urined GnTobNet(Ak)CTeNiSxtS A/c1/P6-v3
2000-05 5/urol Wound GnTobNet(Ak)CTeSxtS (n = 2) A/c1/P6
2000-05 5/urol Urined NetCTeSxtS (n = 2) A/c1/P6-v2
2001-02 4/pulm Sputumd TobNetCTeSxtS A/c2/P7
2001-05 6/urol Urined NetSxtS A/c1/P8
2001-05 6/urol Urined TobNetAkCTeNiSxtS A/c2/P7
2001-05 6/urol Urined GnTobNetAkCSxtS A/c1/P8
2001-12 7/urol Urined NetSxtS A/c4/P9
2002-03 8/? Urined CTeSxtS A/c2/P10
2002-09 9/? Bloodd TobNetTeNi /SHV5 B/c6/P42
2002-09 10/gm Urine, bloodd GnTobNetAkCTeSxtS (n = 2) A/c1/P11
2002-10 11/surg Woundd GnCTeSxtS A/c1/P12
2002-10 12/ICU Tracheal aspirated GnTobCTeSxtS A/c2/P13
2002-10 13/gp Urined TobNetTeNiSxtS (n = 2) A/c2/P14
2002-11 2/gm Bloodd GnTobNetCTeSxtS A/c1/P15
2002-11 14/? Urined GnTobNetCTeSxtS A/c2/P16
2002-11 14/? Urined GnNetCTeNiSxt /SHV5 C/c7/P43
2003-04 9/? Woundd TeSxtS A/c1/P17
2003-04 9/emerg Urine, wound, bloodd TobNet(Ak)CTeSxtS (n = 4) A/c1/P17
2003-08 15/gm Urined CTeSxtS A/c2/P18
2003-10 16/gm Urined GnTobNetSxtS A/c3/P19
2003-11 16/gm Woundd NetCTeSxtS A/c1/P20
2003-12 9/ICU Tracheal aspirated GnTobNet(Ak)CTeSxtS A/c1/P21
2004-01 17/ICU Hand contact surface CTeSxtS A/c2/P22
2004-01 17/ICU Throat swabs CTeSxtS (n = 3) A/c2/P22
2004-01 17/ICU Nasopharyngeal swabs CTeSxtS (n = 2) A/c2/P22
2004-01 17/ICU Tracheal aspirated CTeSxtS A/c2/P22
2004-01 17/ICU Throat swab (nurse) CTeSxtS A/c2/P22
2004-04 17/ICU Drain CTeSxtS A/c2/P22-v1
2004-01 18/TB Transthoracal draind GnTobNetCTeSxtS A/c1/P23
2004-02 19/ICU Punctured GnTobSxtS A/c1/P24
2004-02 19/urol gait Urined GnTobNetTeSxtS A/c1/P25
2004-02 19/urol gait Urined GnTobTeNiSxtS A/c1/P24-v1
2004-06 19/urol gait Urined GnTobNetCTeNiSxtS A/c1/P24-v1
2004-07,-08 19/urol gait Urine GnTobTeNiSxtS (n = 6) A/c1/P24-v2
2004-08 19/urol gait Urine GnTobTeNiSxtS A/c1/P24-v3
2004-08 19/urol gait Urined GnTobNetTeNiSxtS A/c1/P24-v2
2004-09 19/urol gait Urined GnTobTeNiSxtS A/c1/P25-v1
2004-02 20/gm IV cannulad TobNetAkCTeNiSxtS A/c1/P35
2004-02 20/ICU Tracheal aspirated CTeNiSxtS A/c2/P36
2004-03 20/ICU Tracheal aspirated GnTobNetAkCTeSxtS A/c2/P36
2004-03 20/ICU Wound GnTobNetAkCTeSxtS A/c2/P36
2004-01 20/neurosurg Tracheal aspirated GnTobNetCTeNiSxtS A/c1/P35
2004-02 20/neurosurg Urined GnTobNetCTeNiSxtS A/c2/P36
2004-08 20/neurosurg Bloodd GnNetTet D/c5/P41
2004-08 20/ICU Throat swabd Ni D/c5/P41
2004-03 20/urol Hand contact surface GnTobCTeNiSxtS A/c1/P35
2004-03 20/urol Watertapd GnTobCTeNiSxtS A/c1/P35
2004-05 21/surg Woundd GnNetCTeSxtS A/c1/P28
2004-05 21/surg Woundd GnTobTeSxtS A/c3/P29
2004-06 21/surg Urined GnTobTeNiSxtS A/c3/P30
2004-02 22/urol Urined GnTobNetSxtS A/c1/P26
2004-06 22/urol Urined GnTobNetSxtS A/c1/P31
2004-04 23/gp Urined CTeSxtS A/c1/P27
2005-01 20/urol gait Urined CTeSxtS A/c1/P32
2005-02 20/traumatol Urined GnNetCTeSxtS A/c1/P34
2005-04 20/urol Bloodd GnTobNetCTeSxtS (n = 2) A/c1/P35,-v1
2005-04 20/urol Urined GnTobNet(Ak)CTeSxtS A/c1/P35
2005-06 20/urol Wound GnTobNet(Ak)CTeSxtS A/c1/P35-v2
2005-02 24/gm Sputumd GnTobNetCTeNiSxtS /CTXM15 A/c1/P33
2005-04 25/stroke Nasopharynxd (swab) TobNetAkCTeNiSxtS A/c1/P37
2005-03 21/dermatol Urined NiSxtS A/c1/P38
2005-08 21/urol gait Urined NetCTeNiSxtS A/c1/P38-v1
2005-11,-12 26/ICU Blood GnTobNetCTeSxtS (n = 5) A/c1/P39
2005-12 26/ICU Tracheal aspirate, wound GnTobNetCTeSxtS (n = 2) A/c1/P39
2005-12 26/ICU Blood, drain GnTobNetCTeSxtS (n = 2) A/c1/P39
2005-12 26/ICU Swang -catheter, blood GnTobNetCTeSxtS (n = 2) A/c1/P39
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65%, 68%, 71.5%, 91%, 96.5% and 97%, respectively. Forty-
three per cent of isolates were resistant to at least seven of
the nine drugs. Incidence rates of nitrofurantoin resistance
were found to be 50% for urine isolates (n = 50) and 14%
for the other 63 isolates.
With the ERIC-PCR, four ERIC types (A–D) could be dis-
tinguished. Type A comprised 109 isolates. Two of the three
ESBL isolates had unique ERIC proﬁles. The fourth type was
distinguished only by the ERIC1R primer.
Forty-three PFGE strains [14] were revealed by XbaI
PFGE. Type A isolates were found to belong to 40 PFGE
strains ranked in four PFGE clusters by the use of the Pear-
son’s coefﬁcient (Table 1: clusters 1, 2, 3 and 4). The three
further ERIC types were 100% concordant with three novel
XbaI PFGE clusters (Table 1: clusters 5, 6 and 7). Fig. 1
shows the Pearson’s tree diagram prepared for the 40 PFGE
strains of type A.
The Pearson’s tree was cut (Fig. 1) and the ﬁrst isolate of
each branch was tested with SpeI and NotI, respectively. The
Dice analysis on the SpeI patterns revealed ‡80% similarity
(Fig. 2), conﬁrming the monoclonal origin of isolates belong-
ing to the epidemic ERIC type. Restriction with NotI gener-
ated double the usual number of fragments on the genomes
of the isolates from ERIC-type A.
Sixty-seven representative isolates (see Table 1) were
selected for further examinations.
The efﬂux pump inhibitor test with Phe-Arg-b-naphtylamide
(PAbN) and organic solvent tolerance test
Five multidrug-resistant isolates and the control strain
(ATCC 13047) did not grow in the presence of cyclohexane
(CH)), ﬁve isolates showed visible growth (CH+/)), and a
further 57 isolates (85%) showed conﬂuent growth (CH+).
By repeated testing with PAbN, ciproﬂoxacin MICs of 14
isolates decreased by 0–1 dilution steps (PAbN)), ciproﬂox-
acin MICs of a further 28 isolates decreased by two dilution
steps (fourfold reduction: PAbN+/)), and ciproﬂoxacin MICs
of the remaining 25 isolates decreased by at least three dilu-
tion steps (at least eightfold reduction: PAbN+).
All the CH) isolates were found to be PAbN). Among
the CH+/) isolates, four were PAbN+ one was PAbN).
Among the CH+ isolates, 8, 28 and 21 isolates were found
to be PAbN), PAbN+/) and PAbN+, respectively. Concor-
dance between the results with CH and PAbN rose from
39% to 73% when the threshold for notability was reduced
from an eightfold or greater reduction of ciproﬂoxacin MIC
in the presence of PAbN [16,17] to a fourfold reduction
[2,18,19].
Ciproﬂoxacin MIC50 values increased progressively from
1997 to 2002: 4 mg/L (n = 1, 1997), 32 mg/L (n = 5, 1998),
64 mg/L (n = 7, 2000), 64 mg/L (n = 5, 2001), 128 mg/L
(n = 9, 2002), 128 mg/L (n = 6, 2003), 128 mg/L (n = 23,
2004), 64 mg/L (n = 11, 2005). Except for the only isolate
from 1997, the MIC90 value was found to be 128 mg/L for
each year. Tetracycline and chloramphenicol MIC testing was
performed on 39 of the 67 representative isolates, those of
ERIC type A, collected from 1997 to the end of 2004. Chl-
oramphenicol MIC50 values seemed to depend rather on the
sender facility than the year of isolation: 64 mg/L (n = 1,
1997), 1024 mg/L (n = 5, 1998), 512 mg/L (n = 7, 2000),
32 mg/L (n = 5, 2001, four of them derived from one sen-
der), 1024 mg/L (n = 7, 2002), 1024 mg/L (n = 6, 2003),
32 mg/L (n = 8, 2004). Tetracycline MIC50 values were found
to be constant (512 mg/L) from 1997 to 2004, except for
2001 (MIC50 (2001) = 32 mg/L). Table 2 shows the MICs plot-
ted against the CH tolerance (a) or the PABN susceptibility
(b). Statistical analyses showed that all the differences seen in
ciproﬂoxacin MICs of any two corresponding groups were
statistically signiﬁcant (Mann–Whitney test), but none of the
differences seen in tetracycline or chloramphenicol MICs
were (Table 2).
Twenty-two E. cloacae clinical isolates of different ERIC
patterns (collected between 1991 and 2004 by the HNCE)
and lacking resistance to third-generation cephalosporins,
TABLE 1. Continued
Isolationa HF ID/depb Sample Antibiogramc
ERIC-type/XbaI
cluster/strain
2005-12 26/ICU Bloodd GnTobNet(Ak)CTeSxtS A/c1/P39
2005-11 26/ICU Bloodd GnTobNetAkCTeSxtS A/c1/P40
2005-11 26/infect gait Urine GnTobNetAkCTeSxtS A/c1/P40
2005-12 26/ICU Bloodd GnTobNetAkCTeSxtS (n = 2) A/c1/P39
aIsolation: years/months of isolations.
bHF ID/dep: identity numbers for healthcare facilities/departments. HF1–4, HF6, 10,25: teaching hospitals, Budapest (Bp). HF5: Secondary/tertiary care hospital, Budapest (Bp)
HF7, 9, 12, 21, 22, 26: county hospitals of No´gra´d, Somogy, Borsod-Abau´j-Zemple´n (BAZ), Veszpre´m, Zala, Gy}or-Moson-Sopron. HF8, 11, 14–17, 19, 20, 24: municipal hospi-
tals of Koma´rom-Esztergom, BAZ, Pest, Bp, Heves, Ba´cs-Kiskun. HF13, 23: general practitioners of BAZ, Zala. HF18: TB sanatorium, Heves. og, obstetrics-gynaecology; gm,
general medicine.
cAntibiogram: resistance patterns. Parentheses: intermediate susceptible isolates. ERIC-types: A–D. XbaI PFGE Pearson’s clusters: PFGE/c1–7. XbaI PFGE strains: PFGE/P1–43.
XbaI PFGE strain-variants (for isolates with £three bands difference): PFGE/P-v.
dThe isolate was selected for CH tolerance and PAbN susceptibility tests with respect to the clinical data and the laboratory tests performed on all the isolates. Among the
isolates listed in the same row, only one was further tested.
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ciproﬂoxacin, or a third, non-b-lactam, non-ﬂuoroquinolone
drug tested in our study, were found to be CH).
PCR-sequencing of QRDRs
The strains showing ciproﬂoxacin MICs ‡4 mg/L in the pres-
ence of PAbN exhibited mutations leading to Ser-83 ﬁ Tyr
and Asp-87 ﬁ Asn changes (ﬁve PAbN-negative isolates
from genotype A with different Cip MICs, ranging from 4 to
64 mg/L in the presence of PAbN) or Ser-83 ﬁ Tyr and
Asp-87 ﬁ Ala changes (isolates of types B and C) in gene
encoding GyrA, and a single mutation generating a Ser-
80 ﬁ Ile change in gene encoding ParC (the same isolates
from types A, B and C). The strains of type D (showing 0.5–
1 mg/L ciproﬂoxacin MICs in the presence of PAbN) had a
single mutation generating a Ser-83 ﬁ Phe change in gyrA,
and no mutations in the parC gene.
Discussion
E. cloacae has been far more rarely involved in large hospital
outbreaks or inter-hospital spreads than in clusters of cases
conﬁned to single hospitalization units. In this study, the epi-
demic spread of one single clone (ERIC-type A) in 11 Hun-
garian counties (that was found highly probable when
analysing the results by XbaI PFGE) was conﬁrmed by SpeI
PFGE. The restriction site of NotI (GC/GGCCGC) harbours
a complementary sequence of a variable number tandem
repeat (VNTR)/short sequence repeat (SSR): (-GCC-) [20].
The results with NotI may indicate the presence of a VNTR/
SSR sequence in an unusually high number of type A isolates.
Comparing resistance patterns and MICs of type A isolates
year by year shows it is feasible that there was persistence
of a common source somewhere in Hungary up to 2005,
when no loss of antimicrobial resistance through the study
period is postulated. That source could be the teaching hos-
pitals or a secondary/tertiary care hospital (HF5).
High-level ciproﬂoxacin resistance of multidrug-resistant
enterobacterial strains was reported many times through
accumulation of various resistance mechanisms in a step-by-
step process (target gene mutations, increased efﬂux activity,
and alteration in porin synthesis resulting in decreased mem-
brane permeability). Mutations in the QRDRs of the gyrA
and parC genes and the role of the AcrAB efﬂux pump were
shown to be involved in ciproﬂoxacin resistance in E. cloacae
as well [2,21,22]. Cyclohexane tolerance was frequently asso-
ciated with MDR involving the AcrAB efﬂux-pump system in
Enterobacteriaceae species [1], but little is known about cyclo-
hexane tolerance in E. cloacae strains. In two consecutive
E. cloacae isolates, the increased expression of MarR and
AcrB resulted in the emergence of cyclohexane tolerance, a
fourfold increase in ciproﬂoxacin, and a twofold increase in
chloramphenicol and tetracycline MICs [2]. The ciproﬂoxacin
and chloramphenicol MIC50 values of the cyclohexane-sensi-
tive strains were found in our study to be fourfold lower
than those of the cyclohexane-tolerant strains, and the tetra-
cycline MIC50 values twofold lower. Twenty-two E. cloacae
clinical isolates of different ERIC patterns lacking resistance
to third-generation cephalosporins, ciproﬂoxacin, or a third,
FIG. 1. The Pearson’s tree diagram prepared for the 40 PFGE
strains of type A (Fig. 1) shows the three clusters that could be dis-
tinguished by the Dice analysis as well (Pearson’s clusters 1-2-4), and
a novel cluster, containing only three isolates (Pearson’s cluster3);
clusters are separated by a black broken line. The similarity by the
Dice coefﬁcient was no more than ‡66% for the 40 PFGE strains,
but the similarities (Dice analysis) for the PFGE strains of Pearson’s
clusters 1-2-4 and for the PFGE strains of Pearson’s clusters 1–3
were found to be ‡74% and ‡72%, respectively, indicating the mono-
clonal origin of type-A isolates [14]. The black scattered line is indic-
ative of 50% similarity (Pearson’s analysis). The grey arrow shows
the cut of the tree made for PFGE examinations with SpeI. SpeI
PFGE was performed on the ﬁrst isolate of each branch. Places of
origin of these isolates are indicated on the tree at the section
points (Bp1: HF1, Bp2: HF2, Bp4: HF4, Bp5: HF5, No´gra´d1: HF7,
BAZ2: HF12, Heves1: HF16, Veszpre´m1: HF21). Bp, Budapest; BAZ,
Borsod-Abau´j-Zemple´n.
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non-b-lactam, non-ﬂuoroquinolone drug tested in our study
were found to be cyclohexane-sensitive in our study.
In addition to the MarA/SoxS/Rob family [1], RamA was
identiﬁed as a transcriptional regulator of the AcrAB efﬂux-
pump in many species [23]. In a recent publication, mutation
in ramR and consequent overproduction of RamA and AcrB
have been found in one mutant laboratory salmonella strain
selected with ciproﬂoxacin to be associated with cyclohex-
ane tolerance, a statistically signiﬁcant, fourfold increase in
ciproﬂoxacin, chloramphenicol and tetracycline, and a two-
fold increase in triclosan MICs [24]. Good correlation of
overexpression of RamA with increased expression of the
AcrAB efﬂux-pump has already been found also in E. cloacae
isolates with decreased susceptibility to tigecycline [25].
PAbN is a widely used efﬂux-pump inhibitor capable of at
least partially reversing the MDR phenotype in Enterobacteria-
ceae. Depending on species, a fourfold or eightfold reduction
in ﬂuoroquinolone MICs in the presence of PAbN was con-
sidered to be an indicator of the efﬂux-pump overexpression
phenotype [2,16–19,22]. Ciproﬂoxacin MIC of an E. cloacae
isolate overexpressing the acrA gene was found to be eight-
fold lower in the presence of PAbN [22]. In our study, a
notable (fourfold or greater) reduction in ciproﬂoxacin MICs
was found in the presence of PAbN in 79% of isolates tested
(isolates from clones A, C and D) and an eightfold or greater
reduction in 37% (isolates from clones A and C). The results
may point to a role in the decreased inﬂux/efﬂux ratio for
high-level ciproﬂoxacin resistance and the MDR phenotype
in these isolates.
The increased efﬂux and the biocide-resistance mecha-
nisms that may be indicated by cyclohexane tolerance may
prolong bacterial survival [16,26,27], so allowing a bacterium
to accumulate other resistance mechanisms. In our study,
the cyclohexane-tolerant isolates were derived from three of
the four multidrug-resistant clones. All the isolates in which
a fourfold or greater reduction of ciproﬂoxacin MICs was
seen in the presence of PAbN showed slender or conﬂuent
growth in the presence of cyclohexane. The high-level cipro-
ﬂoxacin and MDR of isolates can only partially be explained
by our results. The ﬁve isolates from type A had identical
mutations in the QRDRs of both of the gyrA and the parC
genes, regardless of how their ciproﬂoxacin MICs differed in
the presence of PAbN (4–64 mg/L). Although the ﬁrst isolate
of the epidemic type was found to be negative by both of
the cyclohexane-tolerance and efﬂux pump-inhibitor tests,
and had the lowest ciproﬂoxacin MIC (4 mg/L) among the
isolates of the epidemic type, a 4 mg/L or a lower ciproﬂox-
acin MIC value could be achieved by the use of PAbN in
only one isolate of type A, while 85% of the tested isolates
of type A had ciproﬂoxacin MICs in the presence of PAbN
signiﬁcantly higher than 4 mg/L (‡16 mg/L). The isolates
showing slender growth in the presence of cyclohexane had
8–16 mg/L ciproﬂoxacin MICs in the presence of PAbN, as
did 79% of cyclohexane-tolerant and four of the ﬁve cyclo-
hexane-sensitive isolates. These results may indicate the
presence of a common, PAbN-independent resistance mech-
anism raising the ciproﬂoxacin MICs to 8–16 mg/L in the
majority of isolates regardless of their cyclohexane tolerance.
In our study, 11 isolates showed 32–64 mg/L ciproﬂoxacin
MICs in the presence of PAbN. Further molecular studies
would be needed to highlight the resistance mechanisms.
Cyclohexane tolerance or at least eightfold reduction in
ciproﬂoxacin MICs in the presence of PAbN was detected in
altogether 91% of the isolates tested. Our results underline
the great importance of rationalizing the use of antimicrobi-
als or biocides and of tight control of healthcare-associated
FIG. 2. SpeI hierarchical tree diagram. Dice tree for the selected isolates (n = 10) and the Lambda concatemers (used as standards). Lane 1: XbaI
Pearson’s cluster1 isolate (Bp2, 1998). Lane 2: the ﬁrst isolate from the XbaI Pearson’s cluster3 (Hevesl, 2003). Lane 3: the second isolate of the XbaI
Pearson’s cluster2 (Bp4, 1998). Lane 4: the ﬁrst provincial isolate (No´gra´dl, 2001, XbaI-Pearson’s cluster4). Lane 5: XbaI Pearson’s cluster2 isolate
(BAZ2, 2002). Lane 6: the ﬁrst isolate of the XbaI Pearson’s cluster2 (Bp2, 1998). Lane 7: the ﬁrst isolate of the ﬁrst cluster of cases (Bp5, 2000, XbaI-
Pearson’s clusterl). Lane 8: the second isolate from the XbaI Pearson’s cluster3 (Veszpre´ml, 2004). Lanes 9 and 10: the ﬁrst and the second isolates of
ERIC-type A (Bpl, Bp2, XbaI-Pearson’s clusterl, 1997–1998). Lanes 11 and 12: Lambda concatemers. (Lane numbering: sequentially from above.)
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infections by multidrug-resistant bacteria, as a means of limit-
ing the spread of multidrug-resistant bacterial clones.
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